Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$250.65 USD

250.65
567,768

+1.34 (0.54%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $251.15 +0.50 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Urmimala Biswas headshot

Can These 4 MedTech Stocks Hit Targets This Earnings Season?

by Urmimala Biswas

Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.

Will Clear Aligner Sales Drive Align Technology's (ALGN) Q2 Earnings?

by Zacks Equity Research

Align Technology's (ALGN) second-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.

Align Technology (ALGN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Holding Align Technology (ALGN) Stock Could Pay Off

by Zacks Equity Research

Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.

Indrajit Bandyopadhyay headshot

4 Stocks to Buy Amid Dental Supplies Industry Challenges

by Indrajit Bandyopadhyay

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.

Nalak Das headshot

Buy These 5 Stocks on the Dip to Gain From Wall Street Rally

by Nalak Das

Five top stocks at attractive valuations are: DELL, OKTA, GPN, ALGN, RBLX.

Are Options Traders Betting On a Big Move In Align Technology (ALGN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Align Technology (ALGN) stock based on the movements in the options market lately.

DaVita (DVA), Nuwellis Extend Pilot Collaboration for Aquadex

by Zacks Equity Research

DaVita (DVA) extends its pilot collaboration with Nuwellis to conduct additional testing of the Aquadex ultrafiltration treatment for adult patients suffering from congestive heart failure and related conditions.

Align Technology (ALGN) Gains From New Alliances, Global Growth

by Zacks Equity Research

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions, including new areas within Africa and Latin America.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

Intuitive Surgical (ISRG) Gets FDA Nod for da Vinci's New Label

by Zacks Equity Research

Intuitive Surgical (ISRG) announces the FDA clearance of revised da Vinci Xi and X Labeling on Radical Prostatectomy.

Indrajit Bandyopadhyay headshot

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

by Indrajit Bandyopadhyay

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Reasons to Add Masimo (MASI) Stock to Your Portfolio Now

by Zacks Equity Research

Masimo's (MASI) R&D activities raise optimism about the stock.

DexCom's (DXCM) G7 CGM System Now Connects to Apple Watch

by Zacks Equity Research

DexCom (DXCM) announces the direct connectivity of its G7 CGM system to Apple Watch for users in the United States, the UK, and Ireland.

Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Stryker's (SYK) LIFEPAK 35 to Offer Advanced Monitoring System

by Zacks Equity Research

Stryker (SYK) announces the launch of LIFEPAK 35 monitor/defibrillator, which is likely to aid emergency responders to reduce cognitive load during demanding situations by improving workflow.

DexCom (DXCM) Declines on Potential Competition for Stelo (revised)

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Stryker's (SYK) Acquisition of Artelon Set to Expand Its Market

by Zacks Equity Research

Stryker (SYK) announces the signing of the definitive agreement to acquire a privately held company, Artelon, to strengthen its foothold in the soft tissue fixation market.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

HealthEquity (HQY) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2025.

Inari's (NARI) Expanding Product Portfolio Offsets Competition

by Zacks Equity Research

Inari's (NARI) VTE products are driving its top line on the back of robust adoption. The company is expanding in additional indications to fuel growth and fight competition.

DexCom (DXCM) Declines on Potential Competition for Stelo

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

ClearPoint's (CLPT) New Products to Boost Neurosurgical Segment

by Zacks Equity Research

ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.

Surmodics (SRDX) Enters Deal to be Acquired by GTCR for $627M

by Zacks Equity Research

Surmodics (SRDX) enters a definitive agreement to be acquired by renowned private equity company GTCR at an estimated total equity valuation of $627 million.